Laura Shawver, Ph.D.

Laura Shawver is president, CEO of Capstan Therapeutics, a biotechnology company focused on mRNA and targeted lipid nanoparticles for cell therapy.

Prior to Capstan Therapeutics, Laura was president and CEO of Silverback Therapeutics, a biopharmaceutical company advancing a pipeline of therapies that are systemically delivered, but locally active and target fundamental disease pathways in cancer, fibrosis and virology, from 2020 through it’s merger with ARS Pharmaceuticals in 2022. Prior to Silverback, Laura was president and CEO of Synthorx, Inc., a company developing engineered cytokines for cancer and autoimmune disorders, from 2017 through its acquisition by Sanofi in 2020. Previously, she was CEO of Cleave Biosciences and an entrepreneur in residence for 5AM Ventures. Earlier in her career, Laura was the CEO and director of Phenomix Corporation and president of SUGEN, Inc. after holding various positions.

Laura is the founder of the non-profit organization, The Clearity Foundation, which helps women with ovarian caner improve their treatment options. As of January 1, 2025, The Clearity Foundation has combined with the Ovarian Cancer Research Alliance (OCRA). Dr. Shawver serves on the board of ARS Pharmaceuticals, Inc. and Relay Therapeutics.

Laura holds a Ph.D. in pharmacology from the University of Iowa.

Ovarian Cancer Research Alliance

Ovarian Cancer Research Alliance (OCRA) is the global leader in research funding and a trailblazer in the race to find a cure for ovarian and gynecologic cancers. Unafraid to challenge accepted wisdom, OCRA has taken powerful stances on everything from new recommendations for prevention to creating innovative, highly effective programs to promote education, advocacy, and awareness.

OCRA’s patient support programs, staffed by highly experienced social workers, are a model in the field. They offer dedicated assistance and empathetic support for those who need it most, no matter where they are in their cancer journey. Our goal is not only to improve treatments and attract the most gifted scientists to the field, but also to support patients and their families to ensure the best possible care and outcomes. We are passionately committed to inspiring hope, advancing science, and moving the world closer to a cure.